Deregulating iron-erythropoiesis regulation: transferrin receptor 2 as potential target for treating anemia in CKD.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37349056.
- Also identified by DOI 10.1016/j.kint.2023.04.017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Both insufficient kidney production of erythropoietin and inflammation-mediated reduction of transferrin-bound iron are major factors in anemia of chronic kidney disease. Improved therapies for anemia in chronic kidney disease may involve modifying regulators of erythropoiesis and iron availability. Olivari et al. show in a mouse model of chronic kidney disease that transferrin receptor 2 in hepatocytes, where it is required for hepcidin production, and in erythroid cells, where it downregulates erythropoietin receptor activity, is a potential therapeutic target.
Medical subject headings
- Anemia
- Erythropoietin
- Renal Insufficiency, Chronic